Collectively, these studies highlight the possible effects of SGLT2 inhibitors on the cardiac non-myocytes, plausibly by systemic actions, which could be harnessed as a specific therapy for diabetic cardiomyopathy. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.